Allergy Therapeutics Future Growth
Future criteria checks 1/6
Allergy Therapeutics is forecast to grow earnings and revenue by 32.8% and 19.2% per annum respectively while EPS is expected to grow by 46.5% per annum.
Key information
32.8%
Earnings growth rate
46.5%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 19.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2026 | 81 | -20 | -7 | 1 | 1 |
| 6/30/2025 | 65 | -32 | -22 | -14 | 1 |
| 6/30/2024 | 55 | -40 | -36 | -32 | N/A |
| 3/31/2024 | 54 | -45 | -36 | -32 | N/A |
| 12/31/2023 | 53 | -50 | -36 | -32 | N/A |
| 9/30/2023 | 56 | -47 | -35 | -31 | N/A |
| 6/30/2023 | 60 | -43 | -34 | -29 | N/A |
| 3/31/2023 | 62 | -36 | -32 | -27 | N/A |
| 12/31/2022 | 64 | -29 | -30 | -25 | N/A |
| 9/30/2022 | 68 | -21 | -24 | -20 | N/A |
| 6/30/2022 | 73 | -14 | -17 | -14 | N/A |
| 3/31/2022 | 76 | -10 | -10 | -7 | N/A |
| 12/31/2021 | 79 | -5 | -4 | -1 | N/A |
| 9/30/2021 | 82 | -1 | 1 | 4 | N/A |
| 6/30/2021 | 84 | 3 | 6 | 9 | N/A |
| 3/31/2021 | 83 | 5 | 7 | 10 | N/A |
| 12/31/2020 | 82 | 7 | 9 | 11 | N/A |
| 9/30/2020 | 80 | 7 | 9 | 12 | N/A |
| 6/30/2020 | 78 | 7 | 10 | 12 | N/A |
| 3/31/2020 | 78 | 8 | 10 | 13 | N/A |
| 12/31/2019 | 77 | 8 | 10 | 13 | N/A |
| 9/30/2019 | 76 | 6 | 6 | 9 | N/A |
| 6/30/2019 | 74 | 3 | 3 | 6 | N/A |
| 3/31/2019 | 73 | 0 | -1 | 2 | N/A |
| 12/31/2018 | 73 | -3 | -4 | -2 | N/A |
| 9/30/2018 | 71 | -5 | -5 | -3 | N/A |
| 6/30/2018 | 68 | -8 | -6 | -4 | N/A |
| 3/31/2018 | 67 | -5 | N/A | -2 | N/A |
| 12/31/2017 | 66 | -3 | N/A | 0 | N/A |
| 9/30/2017 | 65 | -3 | N/A | 0 | N/A |
| 6/30/2017 | 64 | -2 | N/A | 0 | N/A |
| 3/31/2017 | 62 | -5 | N/A | -3 | N/A |
| 12/31/2016 | 60 | -7 | N/A | -7 | N/A |
| 9/30/2016 | 54 | -10 | N/A | -9 | N/A |
| 6/30/2016 | 49 | -13 | N/A | -12 | N/A |
| 3/31/2016 | 46 | -10 | N/A | -7 | N/A |
| 12/31/2015 | 44 | -6 | N/A | -3 | N/A |
| 9/30/2015 | 44 | -3 | N/A | 0 | N/A |
| 6/30/2015 | 43 | 0 | N/A | 3 | N/A |
| 3/31/2015 | 43 | 1 | N/A | 3 | N/A |
| 12/31/2014 | 43 | 2 | N/A | 4 | N/A |
| 9/30/2014 | 42 | 1 | N/A | 3 | N/A |
| 6/30/2014 | 42 | 1 | N/A | 2 | N/A |
| 3/31/2014 | 41 | 1 | N/A | 3 | N/A |
| 12/31/2013 | 41 | 2 | N/A | 3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGYT.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGYT.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGYT.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGYT.F's revenue (19.2% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: AGYT.F's revenue (19.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGYT.F's Return on Equity is forecast to be high in 3 years time